{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T04:26:36Z","timestamp":1786854396479,"version":"build-2736575974"},"reference-count":41,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01AI145542"],"award-info":[{"award-number":["R01AI145542"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01AI163042"],"award-info":[{"award-number":["R01AI163042"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01AI158160"],"award-info":[{"award-number":["R01AI158160"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R61AI88553"],"award-info":[{"award-number":["R61AI88553"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P50AA030407"],"award-info":[{"award-number":["P50AA030407"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"award":["R01AI145542"],"award-info":[{"award-number":["R01AI145542"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01AI163042"],"award-info":[{"award-number":["R01AI163042"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01AI158160"],"award-info":[{"award-number":["R01AI158160"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R61AI88553"],"award-info":[{"award-number":["R61AI88553"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]},{"award":["P50AA030407"],"award-info":[{"award-number":["P50AA030407"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>Chronic hepatitis B (CHB) infection is a major risk factor for progressive cirrhosis and hepatocellular carcinoma. Persistent virus-induced inflammation alters liver function, leading to accelerated disease and increased mortality. Although lifelong treatment with nucleos(t)ide analogs (NAs) is highly effective at suppressing viral replication, covalently closed circular DNA (cccDNA) persists in hepatocytes to sustain chronic infection, underscoring the need for better interventions and combination therapies. The durable suppression of viral replication and restoration of immune responses through long-acting (LA) therapies offer a promising strategy for sustained HBV control. We transformed tizoxanide (TIZ), a broad-spectrum anti-infective and immunomodulatory agent, into a LA lipophilic prodrug formulation (NM2TIZ) for intramuscular or subcutaneous administration. NM2TIZ exhibited long-term stability during storage and was evaluated in AAV-HBV mice using monotherapy and combination therapy approaches with an LA tenofovir prodrug formulation (NM5TFV). NM5TFV reduced the HBV DNA levels by &gt;2 log10 fold. Furthermore, coadministration of NM5TFV with M2TIZ reduced the expression of liver inflammasomes and profibrotic markers. The NM5TFV and NM2TIZ combination reduced HBV replication, inflammation, and fibrogenesis in AAV-HBV-transduced mice.<\/jats:p>","DOI":"10.3390\/biology15161391","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:08:29Z","timestamp":1786694909000},"page":"1391","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combinatorial Therapy with Long-Acting Tenofovir and Tizoxanide Controls Viral Replication and Liver Inflammation in a Murine AAV-HBV Model of Chronic Hepatitis B"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9686-5054","authenticated-orcid":false,"given":"Mojisola O.","family":"Ogunnaike","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA"},{"name":"Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashrafi","family":"Sultana","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samiksha","family":"Raut","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Bybee","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-0370","authenticated-orcid":false,"given":"Howard E.","family":"Gendelman","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1484-9331","authenticated-orcid":false,"given":"Benson J.","family":"Edagwa","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7498-0556","authenticated-orcid":false,"given":"Natalia A.","family":"Osna","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7339-8732","authenticated-orcid":false,"given":"Larisa Y.","family":"Poluektova","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE 68198, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2026, June 01). Hepatitis B. Available online: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.24804","article-title":"Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin","volume":"56","author":"Kowdley","year":"2012","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/jvh.13217","article-title":"Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis","volume":"27","author":"Platt","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41575-022-00724-5","article-title":"The scientific basis of combination therapy for chronic hepatitis B functional cure","volume":"20","author":"Lim","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"eadw2286","DOI":"10.1126\/sciadv.adw2286","article-title":"A scalable ultra-long-acting tenofovir phosphonate prodrug sustains HBV suppression","volume":"11","author":"Raut","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"eade9582","DOI":"10.1126\/sciadv.ade9582","article-title":"An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression","volume":"8","author":"Das","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Allweiss, L., and Dandri, M. (2017). The Role of cccDNA in HBV Maintenance. Viruses, 9.","DOI":"10.3390\/v9060156"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: Current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"a021501","DOI":"10.1101\/cshperspect.a021501","article-title":"Antiviral therapies and prospects for a cure of chronic hepatitis B","volume":"5","author":"Zoulim","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0377-1237(11)80020-1","article-title":"Nitazoxanide: A Broad Spectrum Antimicrobial","volume":"67","author":"Singh","year":"2011","journal-title":"Med. J. Armed Forces India"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jiph.2016.04.001","article-title":"Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus","volume":"9","author":"Rossignol","year":"2016","journal-title":"J. Infect. Public Health"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.antiviral.2007.08.005","article-title":"Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication","volume":"77","author":"Korba","year":"2008","journal-title":"Antivir. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jcmgh.2018.10.010","article-title":"Inhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx-DDB1 Interaction","volume":"7","author":"Sekiba","year":"2019","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1128\/AAC.00078-08","article-title":"Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide","volume":"52","author":"Korba","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3748\/wjg.15.1805","article-title":"Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides","volume":"15","author":"Keeffe","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1206951","DOI":"10.3389\/fmicb.2023.1206951","article-title":"The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: Effect on the viral spike glycoprotein","volume":"14","author":"Piacentini","year":"2023","journal-title":"Front. Microbiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"20953","DOI":"10.18632\/oncotarget.25104","article-title":"DHX9 regulates production of hepatitis B virus-derived circular RNA and viral protein levels","volume":"9","author":"Sekiba","year":"2018","journal-title":"Oncotarget"},{"key":"ref_20","unstructured":"Tan, Y.C., Shen, L., Khine, H.H.T.W., Tay, A., Andrenada, C., Rossignol, J.F., Rossignol, C., and Lim, S.G. (2022, January 22\u201326). Randomized double-blind study of Nitazoxanide for virologically suppressed HBeAg negative Chronic Hepatitis B. Proceedings of the International Liver Congress\u2122 2022 (European Association for the Study of the Liver), London, UK. Poster No. SAT-446."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/09205063.2020.1844506","article-title":"Enhancing the solubility of nitazoxanide with solid dispersions technique: Formulation, evaluation, and cytotoxicity study","volume":"32","author":"Sood","year":"2021","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"766534","DOI":"10.3389\/fimmu.2021.766534","article-title":"In Vivo Mouse Models for Hepatitis B Virus Infection and Their Application","volume":"12","author":"Du","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4049\/jimmunol.186.Supp.105.24","article-title":"A mouse model of T cell dysfunction in chronic Hepatitis B","volume":"186","author":"Tao","year":"2011","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/acer.14740","article-title":"Ethanol attenuates presentation of cytotoxic T-lymphocyte epitopes on hepatocytes of HBV-infected humanized mice","volume":"46","author":"Ganesan","year":"2022","journal-title":"Alcohol Clin. Exp. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s10753-019-00994-3","article-title":"Tizoxanide Inhibits Inflammation in LPS-Activated RAW264.7 Macrophages via the Suppression of NF-\u03baB and MAPK Activation","volume":"42","author":"Shou","year":"2019","journal-title":"Inflammation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"116205","DOI":"10.1016\/j.bcp.2024.116205","article-title":"The antiprotozoal drug nitazoxanide improves experimental liver fibrosis in mice","volume":"224","author":"Liu","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?","volume":"76","author":"Wong","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","article-title":"Hepatitis B cure: From discovery to regulatory approval","volume":"67","author":"Lok","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Woo, Y., Ma, M., Okawa, M., and Saito, T. (2024). Hepatocyte Intrinsic Innate Antiviral Immunity against Hepatitis Delta Virus Infection: The Voices of Bona Fide Human Hepatocytes. Viruses, 16.","DOI":"10.3390\/v16050740"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/cmi.2015.97","article-title":"Hepatocytes: A key cell type for innate immunity","volume":"13","author":"Zhou","year":"2016","journal-title":"Cell Mol. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/cmi.2013.43","article-title":"A mouse model for HBV immunotolerance and immunotherapy","volume":"11","author":"Yang","year":"2014","journal-title":"Cell Mol. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1421712","DOI":"10.3389\/fimmu.2025.1421712","article-title":"AAV-HBV mouse model replicates the intrahepatic immune landscape of chronic HBV patients at single-cell level","volume":"16","author":"Pierson","year":"2025","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.virs.2023.10.007","article-title":"Recent advances in understanding T cell activation and exhaustion during HBV infection","volume":"38","author":"Wang","year":"2023","journal-title":"Virol. Sin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.27332","article-title":"Hepatic inflammation and fibrosis: Functional links and key pathways","volume":"61","author":"Seki","year":"2015","journal-title":"Hepatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jhep.2022.12.014","article-title":"Discovery of a first-in-class orally available HBV cccDNA inhibitor","volume":"78","author":"Wang","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"10425","DOI":"10.1038\/s41598-018-28172-9","article-title":"Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: Role of glycoprotein-specific thiol oxidoreductase ERp57","volume":"8","author":"Piacentini","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.mib.2013.03.002","article-title":"Differences in the repertoire, regulation and function of Toll-like Receptors and inflammasome-forming Nod-like Receptors between human and mouse","volume":"16","author":"Ariffin","year":"2013","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jhep.2016.12.024","article-title":"Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B","volume":"66","author":"Testoni","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"106441","DOI":"10.1016\/j.antiviral.2026.106441","article-title":"Therapeutic vaccination for chronic hepatitis B: Why most vaccines failed and what may work","volume":"252","author":"Bertoletti","year":"2026","journal-title":"Antivir. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2515131","article-title":"Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection","volume":"394","author":"Hou","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.3350\/cmh.2024.0855","article-title":"Prospect of emerging treatments for hepatitis B virus functional cure","volume":"31","author":"Hui","year":"2025","journal-title":"Clin. Mol. Hepatol."}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/15\/16\/1391\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T04:13:46Z","timestamp":1786853626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/15\/16\/1391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":41,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["biology15161391"],"URL":"https:\/\/doi.org\/10.3390\/biology15161391","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}